Immune cells take on advanced tumors in new trial

NCT ID NCT06144671

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated May 16, 2026 · Updated 1 time

Summary

This study tests a new treatment called GT201 for people with advanced solid tumors. GT201 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and then given back to fight the cancer. The trial aims to find a safe dose and see if it can shrink tumors. About 18 adults with advanced solid tumors will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
RECRUITING

Beijing, Beijing Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Union Hospital Tongji Medical College Huazhong University Of Science And Technology
RECRUITING

Wuhan, Hubei, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, 610000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR, ADULT